PT1506234E - Misturas de lípidos sintéticos melhoradas para a preparação de um surfactante reconstituído. - Google Patents
Misturas de lípidos sintéticos melhoradas para a preparação de um surfactante reconstituído. Download PDFInfo
- Publication number
- PT1506234E PT1506234E PT03727469T PT03727469T PT1506234E PT 1506234 E PT1506234 E PT 1506234E PT 03727469 T PT03727469 T PT 03727469T PT 03727469 T PT03727469 T PT 03727469T PT 1506234 E PT1506234 E PT 1506234E
- Authority
- PT
- Portugal
- Prior art keywords
- dppc
- reconstituted surfactant
- popg
- surfactant
- mixture
- Prior art date
Links
- 239000004094 surface-active agent Substances 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 16
- 150000002632 lipids Chemical class 0.000 title description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 26
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims abstract description 11
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims abstract description 11
- 239000003580 lung surfactant Substances 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 230000004064 dysfunction Effects 0.000 claims abstract description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 44
- PAZGBAOHGQRCBP-ZCXUNETKSA-N 1-Palmitoyl-2-oleoylglycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-ZCXUNETKSA-N 0.000 claims description 31
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 13
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 11
- 239000007788 liquid Substances 0.000 abstract description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 44
- 235000021314 Palmitic acid Nutrition 0.000 description 22
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 22
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 14
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 4
- 108010093965 Polymyxin B Proteins 0.000 description 4
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229960003548 polymyxin b sulfate Drugs 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 2
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940092456 curosurf Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 229940063649 survanta Drugs 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 1
- PAZGBAOHGQRCBP-HGWHEPCSSA-N 1-hexadecanoyl-2-[(9Z)-octadec-9-enoyl]-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-HGWHEPCSSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- -1 palmitoyl oleyl phospholipid Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000015227 regulation of liquid surface tension Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002MI001058A ITMI20021058A1 (it) | 2002-05-17 | 2002-05-17 | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1506234E true PT1506234E (pt) | 2007-05-31 |
Family
ID=11449919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT03727469T PT1506234E (pt) | 2002-05-17 | 2003-05-12 | Misturas de lípidos sintéticos melhoradas para a preparação de um surfactante reconstituído. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7511011B2 (enExample) |
| EP (1) | EP1506234B1 (enExample) |
| JP (1) | JP4883906B2 (enExample) |
| KR (1) | KR101028927B1 (enExample) |
| CN (1) | CN100347193C (enExample) |
| AT (1) | ATE353919T1 (enExample) |
| AU (1) | AU2003233320B2 (enExample) |
| CA (1) | CA2486152C (enExample) |
| CY (1) | CY1106667T1 (enExample) |
| DE (1) | DE60311798T2 (enExample) |
| DK (1) | DK1506234T3 (enExample) |
| EA (1) | EA007928B1 (enExample) |
| ES (1) | ES2282627T3 (enExample) |
| HR (1) | HRP20041058B1 (enExample) |
| IL (2) | IL165239A0 (enExample) |
| IT (1) | ITMI20021058A1 (enExample) |
| MA (1) | MA27960A1 (enExample) |
| MX (1) | MXPA04011369A (enExample) |
| NZ (1) | NZ536606A (enExample) |
| PL (1) | PL209649B1 (enExample) |
| PT (1) | PT1506234E (enExample) |
| SI (1) | SI1506234T1 (enExample) |
| TN (1) | TNSN04219A1 (enExample) |
| UA (1) | UA79609C2 (enExample) |
| WO (1) | WO2003097695A1 (enExample) |
| ZA (1) | ZA200409215B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| ATE413178T1 (de) | 2003-03-24 | 2008-11-15 | Actimis Pharmaceuticals Inc | 2-phenoxy- und 2-phenylsulfanyl-benzenesulfonamid derivate mit ccr3 antagonistischer aktivität zur behandlung von asthma und anderen entzündlichen oder immunologischen erkrankungen |
| EP1481665A1 (en) * | 2003-05-30 | 2004-12-01 | CHIESI FARMACEUTICI S.p.A. | Novel lipid mixtures for synthetic surfactants |
| UA76074C2 (en) * | 2005-11-09 | 2006-06-15 | O V Palladin Inst Of Biochemis | Calmophil, pharmaceutical composition for substitution therapy aimed at recovering malfunctioned surfactant system of lungs |
| BRPI0715317B1 (pt) | 2006-10-13 | 2021-10-05 | Chiesi Farmaceutici S.P.A. | Surfactantes reconstituídos com propriedades aperfeiçoadas |
| EP2142196A4 (en) | 2007-03-29 | 2010-06-30 | Nat Jewish Health | SURFACTANTLIPIDS, COMPOSITIONS AND THEIR USE |
| EP1997502A1 (en) * | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
| EP2022798A1 (en) * | 2007-08-09 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Synthetic pulmonary surfactant peptides |
| US8287887B2 (en) | 2008-04-02 | 2012-10-16 | The University Of Tokushima | Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same |
| US8399406B2 (en) * | 2009-06-05 | 2013-03-19 | Chiesi Farmaceutici S.P.A. | Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C) |
| EP2611418A2 (en) * | 2010-08-30 | 2013-07-10 | F.Hoffmann-La Roche Ag | Tetranectin-apolipoprotein a-1, lipid particles containing it and its use |
| BR112013033562A2 (pt) | 2011-08-25 | 2017-02-14 | Hoffmann La Roche | proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas |
| BR112015009486B1 (pt) | 2012-11-21 | 2022-06-14 | Chiesi Farmaceutici S.P.A | Surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0706374B1 (en) * | 1993-06-30 | 1997-12-10 | Genentech, Inc. | Method for preparing liposomes |
| AU2322097A (en) * | 1996-03-27 | 1997-10-17 | Ortho Pharmaceutical Corporation | Lyophilized pulmonary surfactant peptide compositions |
| IT1308180B1 (it) * | 1999-02-12 | 2001-12-07 | Chiesi Farma Spa | Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante |
| AU2001245848A1 (en) * | 2000-03-15 | 2001-10-23 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
| CA2405811C (en) * | 2000-04-12 | 2011-09-27 | Altana Pharma Ag | Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| EP1997502A1 (en) | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
| EP2022798A1 (en) | 2007-08-09 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Synthetic pulmonary surfactant peptides |
-
2002
- 2002-05-17 IT IT2002MI001058A patent/ITMI20021058A1/it unknown
-
2003
- 2003-05-12 CN CNB038112531A patent/CN100347193C/zh not_active Expired - Lifetime
- 2003-05-12 AT AT03727469T patent/ATE353919T1/de active
- 2003-05-12 HR HRP20041058AA patent/HRP20041058B1/hr not_active IP Right Cessation
- 2003-05-12 EP EP03727469A patent/EP1506234B1/en not_active Expired - Lifetime
- 2003-05-12 WO PCT/EP2003/004937 patent/WO2003097695A1/en not_active Ceased
- 2003-05-12 ES ES03727469T patent/ES2282627T3/es not_active Expired - Lifetime
- 2003-05-12 PL PL372751A patent/PL209649B1/pl unknown
- 2003-05-12 IL IL16523903A patent/IL165239A0/xx unknown
- 2003-05-12 PT PT03727469T patent/PT1506234E/pt unknown
- 2003-05-12 SI SI200330756T patent/SI1506234T1/sl unknown
- 2003-05-12 US US10/512,869 patent/US7511011B2/en not_active Expired - Lifetime
- 2003-05-12 DK DK03727469T patent/DK1506234T3/da active
- 2003-05-12 CA CA2486152A patent/CA2486152C/en not_active Expired - Lifetime
- 2003-05-12 AU AU2003233320A patent/AU2003233320B2/en not_active Expired
- 2003-05-12 NZ NZ536606A patent/NZ536606A/en not_active IP Right Cessation
- 2003-05-12 DE DE60311798T patent/DE60311798T2/de not_active Expired - Lifetime
- 2003-05-12 JP JP2004506367A patent/JP4883906B2/ja not_active Expired - Lifetime
- 2003-05-12 KR KR1020047018528A patent/KR101028927B1/ko not_active Expired - Lifetime
- 2003-05-12 EA EA200401385A patent/EA007928B1/ru unknown
- 2003-05-12 MX MXPA04011369A patent/MXPA04011369A/es active IP Right Grant
- 2003-12-05 UA UA20041109233A patent/UA79609C2/uk unknown
-
2004
- 2004-11-11 TN TNP2004000219A patent/TNSN04219A1/en unknown
- 2004-11-16 MA MA27946A patent/MA27960A1/fr unknown
- 2004-11-16 IL IL165239A patent/IL165239A/en active IP Right Grant
- 2004-11-17 ZA ZA200409215A patent/ZA200409215B/xx unknown
-
2007
- 2007-04-26 CY CY20071100558T patent/CY1106667T1/el unknown
-
2008
- 2008-03-06 US US12/043,177 patent/US7842664B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7842664B2 (en) | Synthetic lipid mixtures for the preparation of a reconstituted surfactant | |
| CN101687006B (zh) | 具有改善特性的重建表面活性剂 | |
| KR102122088B1 (ko) | 재구성된 폐 계면활성제 | |
| BRPI1010120B1 (pt) | Composição surfactante reconstituída melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante (sp-c) | |
| BRPI0715317B1 (pt) | Surfactantes reconstituídos com propriedades aperfeiçoadas | |
| ES2380046T3 (es) | Régimen para el tratamiento con tensioactivos para tratar o prevenir la displasia broncopulmonar | |
| US20090170758A1 (en) | Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties | |
| US10124015B2 (en) | Surfactant composition | |
| KR101721309B1 (ko) | 계면활성 단백질 ｂ(ｓｐ－ｂ) 및 계면활성 단백질 ｃ(ｓｐ－ｃ)의 유사체를 포함하는 합성 폐 계면활성제 조성물 | |
| KR101784651B1 (ko) | 계면활성 단백질 ｂ(ｓｐ－ｂ) 및 계면활성 단백질 ｃ(ｓｐ－ｃ)의 유사체를 포함하는 합성 폐 계면활성제 조성물 | |
| KR20190039933A (ko) | 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제 | |
| HK1079221B (en) | Improved synthetic lipid mixtures for the preparation of a reconstituted surfactant |